Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Transcriptome Sequencing and Identification of Cytochrome P450 Monooxygenases Involved in the Biosynthesis of Maslinic Acid and Corosolic Acid in Avicennia Marina
Researchers found two enzymes in Avicennia marina that help produce maslinic acid and corosolic acid, which have medicinal benefits.
research Identification of a Cyclosporine-Specific P450 Hydroxylase Gene Through Targeted Cytochrome P450 Complement Disruption in Sebekia Benihana
A gene in Sebekia benihana, CYP-sb21, is needed for a specific reaction on the drug Cyclosporine A, which could be important for hair growth without affecting the immune system.
research Structure-Guided Manipulation of the Regioselectivity of the Cyclosporine A Hydroxylase CYP-sb21 from Sebekia Benihana
Scientists improved an enzyme to better produce a hair growth-promoting chemical from an immunosuppressant.
research A Novel Regio-Specific Cyclosporin Hydroxylase Gene Revealed Through the Genome Mining of Pseudonocardia Autotrophica
Scientists found a new gene in a bacterium that can modify an immunosuppressant drug, potentially helping to treat hair loss.
research Novel Type 1 5a-Reductase Inhibitors With Antiproliferative Potential On LNCaP Cells
New compounds may help treat prostate cancer by reducing cell growth.
Community Join
5 / 203 resultscommunity Follicum releases some data from previous phase 2a trial
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.